Fax: (011) 34 923 292624
Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome†
Article first published online: 2 JUN 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 24, pages 5529–5537, 15 December 2011
How to Cite
Gonzalez-Porras, J. R., Cordoba, I., Such, E., Nomdedeu, B., Vallespi, T., Carbonell, F., Luño, E., Ardanaz, M., Ramos, F., Pedro, C., Gomez, V., de Paz, R., Sanchez-Barba, M., Sanz, G. F., del Cañizo, a. C. and on behalf of the Spanish Myelodysplastic Syndrome Registry (2011), Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer, 117: 5529–5537. doi: 10.1002/cncr.26173
J.R.G.-P. and C.d.C. conceived the study; M.S.-B., I.C., and J.R.G.-P. performed the statistical analysis; J.R.G.-P. wrote the paper; I.C., E.S., B.N., T.V., F.C., E.L., M.A., F.R., C.P., V.G., R.d.P., G.F.S., and C.d.C. included the patients, collected the data, and performed a critical revision of the paper; and G.F.S. and C.d.C. approved the final version of the paper. We thank R. Andreu, V. Marco, M. Tormo, S. Bonanad, J. de la Serna, J.A. Muñoz, L. Benlloch, D. Costa, J. Bueno, T. Bernal, all members of the Spanish Myelodysplastic Syndrome Registry, and P. Mason for their excellent technical assistance.
- Issue published online: 2 DEC 2011
- Article first published online: 2 JUN 2011
- Manuscript Accepted: 8 MAR 2011
- Manuscript Revised: 23 FEB 2011
- Manuscript Received: 31 JAN 2011
- myelodysplastic syndrome;
Thrombocytopenia is very common in myelodysplastic syndrome (MDS); however, its clinical impact in low-risk patients remains controversial.
The authors analyzed the incidence and prognostic significance of thrombocytopenia at diagnosis in 2565 de novo MDS patients included in the Spanish MDS Registry.
Thrombocytopenia (platelet count <100 × 109/L) was identified in 842 patients (32.8%). Severe thrombocytopenia (platelet count <30 × 109/L) was observed in 7.1% of patients and was significantly associated with a higher-risk World Health Organization subtype (P = .026) and intermediate-2/high-risk International Prognostic Scoring System (IPSS) score (P = .046). Severe thrombocytopenia was the most important prognostic factor and had negative effects on the low/intermediate-1 risk group. Median overall survival of patients with a platelet count <30 and ≥30 × 109/L was 16 months and 71 months, respectively (hazard ratio, 4.66; 95% confidence interval, 2.74-7.90; P < .0001). The negative effect of severe thrombocytopenia in low/intermediate-1 risk patients was caused by increased risk of bleeding.
MDS patients with low/intermediate-1 IPSS risk score and severe thrombocytopenia should no longer be regarded as low risk, and must be considered for disease-altering approaches at diagnosis. Cancer 2011;. © 2011 American Cancer Society.